Table 2. Estimated Base-Case Cost and Utility Outcomes After Modeling Over the Lifetime Horizon.
| Analysis perspectives | Cost, $a | LYs | QALYs | Incremental | ICER per QALY, $a | |
|---|---|---|---|---|---|---|
| Costs, $a | QALYs | |||||
| Base case | ||||||
| Health care sector perspectives | ||||||
| Axicabtagene ciloleucel (2L) | 678 903 | 8.01 | 4.53 | 59 754 | 0.60 | 99 101 |
| Standard care | 619 149 | 7.50 | 3.93 | NA | NA | NA |
| Tisagenlecleucel (2L) | 534 426 | 3.16 | 2.02 | 37 803 | −0.02 | Dominatedb |
| Standard care | 496 623 | 3.45 | 2.04 | NA | NA | NA |
| Tisagenlecleucel (≥3L) | 489 767 | 7.66 | 3.86 | 271 399 | 2.14 | 126 593 |
| Standard care | 218 368 | 3.20 | 1.72 | NA | NA | NA |
| Societal perspectives | ||||||
| Axicabtagene ciloleucel (2L) | 688 507 | 8.01 | 4.55 | 59 076 | 0.60 | 97 977 |
| Standard care | 629 431 | 7.50 | 3.94 | NA | NA | NA |
| Tisagenlecleucel (2L) | 543 578 | 3.16 | 2.02 | 39 480 | −0.02 | Dominatedb |
| Standard care | 504 098 | 3.45 | 2.04 | NA | NA | NA |
| Tisagenlecleucel (≥3L) | 499 457 | 7.66 | 3.86 | 274 442 | 2.14 | 128 012 |
| Standard care | 225 016 | 3.20 | 1.72 | NA | NA | NA |
| No crossover scenario | ||||||
| Health care sector perspectives | ||||||
| Axicabtagene ciloleucel (2L) | 701 407 | 10.17 | 5.31 | 428 745 | 1.98 | 216 790 |
| Standard care | 272 661 | 7.36 | 3.33 | NA | NA | NA |
| Societal perspectives | ||||||
| Axicabtagene ciloleucel (2L) | 710 450 | 10.17 | 5.31 | 432 933 | 1.98 | 218 907 |
| Standard care | 277 517 | 7.36 | 3.33 | NA | NA | NA |
| Crossover with improved progression-free survival scenario | ||||||
| Health care sector perspective | ||||||
| Axicabtagene ciloleucel (2L) | 671 496 | 8.01 | 4.53 | 75 950 | 0.60 | 125 962 |
| Standard care | 595 546 | 7.50 | 3.93 | NA | NA | NA |
| Societal perspective | ||||||
| Axicabtagene ciloleucel (2L) | 681 391 | 8.01 | 4.53 | 74 122 | 0.60 | 122 931 |
| Standard care | 607 269 | 7.50 | 3.93 | NA | NA | NA |
Abbreviations: ICER, incremental cost-effectiveness ratio; L, line of therapy; LY, life-years; NA, not applicable; QALY, quality-adjusted life-years.
a
Costs are provided in adjusted 2021 US dollars.
b
One treatment is considered dominated by the other when it results in incremental costs but decremental effectiveness.